Drug Profile
Pegfilgrastim biosimilar - Primrose Bio
Alternative Names: PF-529Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Pfenex - Stelis Biopharma (JV)
- Developer Primrose Bio
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Neutropenia
Most Recent Events
- 18 Sep 2023 Primordial Genetics has merged with Pelican Expression Technology to form Primrose Bio
- 01 Oct 2020 Pfenex has been acquired by Ligand Pharmaceuticals
- 13 Jun 2019 Pegfilgrastim biosimilar - Pfenex is available for licensing as of 01 Nov 2017. https://www.pfenex.com/